Predictor Variables of Developing Anterior Pituitary Deficiencies in a Group of Paediatric Patients with Central Diabetes Insipidus and Langerhans Cell Histiocytosis

Elisa Vaiani a Carmen Malossetti a Lina Margarita Vega a Pedro Zubizarreta b Jorge Braier b Alicia Belgorosky a

a Endocrine Service and b Hematology-Oncology Service, Hospital de Pediatria Garrahan, Buenos Aires, Argentina

Keywords
Paediatric Langerhans cell histiocytosis · Anterior pituitary deficiency · Diabetes insipidus

Abstract

Background: Langerhans cell histiocytosis (LCH) is a rare histiocytic disorder of unknown etiopathogenesis. Central diabetes insipidus (CDI) is the most frequent endocrine manifestation and is a known risk factor for the development of further anterior pituitary hormone deficiencies (APD). However, not all CDI patients develop APD, as observed during prolonged periods of follow-up. Aim: To find predictors of developing APD in LCH children with CDI followed in our institution. Methods: We retrospectively analysed 44 patients over a median period (quartiles) of 12.3 years (8.79–14.24). Patients were subdivided into group 1 and group 2, according to absence or presence of APD, respectively. The main variables studied were: (1) chronological age (CA) at LCH diagnosis, (2) the primary site of LCH at diagnosis: low risk (LR) and multisystemic risk organs, and (3) the presence of reactivation. Results: Multivariate Cox regression analysis showed that APD was positively associated with CA at LCH diagnosis [relative risk (RR) 1.14, p < 0.01], the LR clinical form (RR 8.6, p < 0.03), and negatively associated with the presence of reactivations (RR 0.3, p < 0.01). Conclusions: Patients with older CA at LCH diagnosis, LR clinical forms, and fewer reactivation episodes might represent a subgroup of paediatric LCH CDI patients with a higher risk of developing APD.

Introduction

Langerhans cell histiocytosis (LCH) is a rare and heterogeneous disease, characterised by accumulation and clonal proliferation of immature dendritic cells (DC) in different organs, with features similar to epidermal Langerhans cells, and expressing antigen CD1a and/or CD 207 (langerin) on immunohistochemistry [1, 2].

LCH affects about 4.1–5 million children per year. More than 50% of cases are diagnosed between 1 and 15 years of age, with a peak between 0 and 4 years [3, 4].

Whether LCH represents a reactive or a neoplastic disease is still a matter of debate. Proinflammatory cytokines and chemokines are known to play a role in LCH, suggesting that LCH is an immune disorder. However, the oncogenic BRAF mutation is also detected in more than half of LCH patients [5].
logic combination between oncogenesis and chronic immune dysregulation [2, 6, 7].

Whatever the primary event, a number of LCH inflammatory cells (T lymphocytes, macrophages, plasma cells, eosinophils, osteoclast-like multinucleated giant cells, and neutrophils) and molecules (cytokines, chemokines, and DC/macrophage-activating factors) with different properties (regulatory, pro-inflammatory, apoptotic, and anti-apoptotic) is consistently present in LCH lesions and, to a certain extent, in the serum of patients with LCH [2, 8].

Most organs or systems of the human body can be affected, but those more frequently involved are the skeleton (80% of cases), the skin (33%), and the pituitary (25%). Other organs involved are the liver, spleen, the hematopoietic system and the lungs (15% each), lymph nodes (5–10%), and the central nervous system (CNS), apart from the neurohypophysis (2–4%) [1].

LCH can be classified according to system involvement as unisystem disease (US), which can be uni- or multifocal and is usually associated with a good prognosis and might require no treatment, or as multisystem disease (MS), which has a poorer prognosis and requires different therapeutic modalities, including cytotoxic drugs and corticoids. The majority of patients with MS have permanent sequelae [9].

Endocrine manifestations in LCH show a particular predilection for involvement of the hypothalam-pituitary axis, leading to central diabetes insipidus (CDI) and/or anterior pituitary dysfunction; these mainly develop in the context of MS [10, 11]. CDI is the most frequent endocrinopathy associated with LCH. The reported incidence is between 15–30% [1, 12, 13]. CDI may become manifest either before, concurrent with, or after LCH diagnosis [14–16]. In addition, patients with DI have a high risk to develop further anterior pituitary hormone deficiencies (APD) during the course of the disease [10, 15]. In keeping with these data, Donadieu et al. [17] described a 5- and 10-year risk of developing GHD of 34.7 and 53.7%, respectively.

In order to find biological predictors of developing APD in LCH children with CDI, we describe the long-term follow-up in LCH children with CDI conducted at our institution from August 1987 to December 2014. We found that APD is more frequent when LCH begins at an older age. In addition, a low-risk clinical form of LCH (US, MS) and less reactivation episodes might represent a subgroup of patients with a higher risk of developing APD.

Patients and Methods

We retrospectively reviewed medical charts of 64 consecutive patients who were diagnosed with DI and LCH at our institution between August 1987 and December 2014. Patients were initially referred to our service with a suspected diagnosis of CDI. This study was approved by the Ethics Committee of the Garrahan Pediatric Hospital. Informed consent was obtained from parents and patients.

LCH diagnosis was confirmed by pathology studies, using both morphological and immunostaining criteria, including CD1a positivity according to the Histiocyte Society criteria. In agreement with the guidelines of the LCH study protocols [1], US was diagnosed when only 1 organ or system was involved. The disease was considered to be unifocal when just 1 site was affected and multifocal, when more than 1 site was involved. The disease was defined as being MS when 2 or more organs or systems were affected. In addition, MS was classified into 2 groups depending on whether risk organs (RO) were compromised.

RO were defined as those organs that, when they are compromised, increase the risk of dying from the disease. They are the liver, spleen, and/or the hematologic system. In these cases, the disease was considered to be RO+. When the organs and systems affected were bone, skin, mucosa, lymph nodes, lungs, or CNS, considered as low risk (LR) organs, the disease was defined as RO−. Skull bone lesions, regarded as “CNS risk lesions” [1], involving the orbital, temporal, sphenoid, ethmoid, or mastoid bones as well as the paranasal sinuses and anterior or middle cranial fossa were documented.

Magnetic resonance images (MRI) at the time of diagnosis were obtained in 51 patients. Neurological abnormalities were categorized as thickening of the pituitary stalk and absence of the neurohypophysis. Tumour lesions were defined as space-occupying lesions involving the hypothalamic-pituitary region or other parts of the brain. These lesions were either isolated or in the context of MS. Radiotherapy applied to the hypothalamic-pituitary region was especially recorded to evaluate the possible effect of radiotherapy on hypothalamic-pituitary function. Disease reactivation was defined according to a previous report [11], and for the purpose of this study, it was considered when the patient had 1 or more new episodes during follow-up.
Endocrine Assessment

Anterior pituitary involvement was considered when at least 1 pituitary hormone axis was affected and there were clinical signs and symptoms of hormone deficiency (polyuria/polydipsia, growth retardation, pubertal delay).

CDI diagnosis was made based on the water deprivation test according to a previous report [18]. GHD was defined as follows: maximum serum GH response less than 6.1 ng/mL (IRP IS80/505) or 4.7 ng/ml (IRP IS 98/5742) to 2 pharmacological tests [19, 20].

In agreement with a previously report [21], gonadotropin deficiency was defined as a low or absent serum FSH and LH response to an LHRH analog test at the pubertal age [chronological age (CA) ≥ 13 or 14 years in girls and boys, respectively]. The hypothalamic-pituitary thyroid and adrenal axes were evaluated by determining serum basal T4, T3, fT4, and TSH, thyroid antibodies, and morning ACTH and cortisol levels, and/or the low-dose ACTH test, respectively [22]. Patients were assessed periodically at least once a year. The date of CDI and APD diagnosis was the date of the first abnormal test.

To be considered the first isolated manifestation of LCH, CDI had to be diagnosed at least 3 months before any extrapituitary involvement.

Study Design

Sixty-four consecutive CDI patients with LCH were included. Sex, CA at LCH, CDI and APD diagnosis, clinical form of LCH presentation, radiotherapy, and MRI findings were recorded.

<table>
<thead>
<tr>
<th>Patients</th>
<th>Total</th>
<th>Group 1</th>
<th>Group 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number</td>
<td>44 (100)</td>
<td>21 (47.7)</td>
<td>23 (52.3)</td>
</tr>
<tr>
<td>CA at LCH diagnosis, years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>2.44</td>
<td>2</td>
<td>3.24*</td>
</tr>
<tr>
<td>Interquartiles</td>
<td>1.7 – 5.01</td>
<td>1.64 – 2.78</td>
<td>2.1 – 6.4</td>
</tr>
<tr>
<td>Clinical presentation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US UF</td>
<td>9</td>
<td>2 (9.5)</td>
<td>7 (30.3)</td>
</tr>
<tr>
<td>US MF</td>
<td>6</td>
<td>4 (19)</td>
<td>2 (8.7)</td>
</tr>
<tr>
<td>MSLR</td>
<td>19</td>
<td>6 (28.6)</td>
<td>13 (56.5)</td>
</tr>
<tr>
<td>MSR</td>
<td>10</td>
<td>9 (42.9)</td>
<td>1 (4.3)</td>
</tr>
<tr>
<td>MRI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absence of neurohypophysis</td>
<td>20 (48.7)</td>
<td>9 (50)</td>
<td>11 (47.8)</td>
</tr>
<tr>
<td>Thickening of the pituitary stalk</td>
<td>18 (43.9)</td>
<td>8 (44)</td>
<td>10 (43.4)</td>
</tr>
<tr>
<td>Arachnoidocele/cyst</td>
<td>2 (4.8)</td>
<td>–</td>
<td>2 (8.6)</td>
</tr>
<tr>
<td>Expansive lesions affecting the HP region</td>
<td>4 (9.7)</td>
<td>–</td>
<td>4 (17.3)</td>
</tr>
<tr>
<td>Expansive lesions in brain or meninges</td>
<td>4 (9.7)</td>
<td>2 (11.1)</td>
<td>2 (8.6)</td>
</tr>
<tr>
<td>Normal</td>
<td>5 (12.1)</td>
<td>3 (16)</td>
<td>2 (8.6)</td>
</tr>
<tr>
<td>CDI diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LCH diagnosis prior</td>
<td>7</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>LCH diagnosis simultaneously</td>
<td>16</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>LCH diagnosis posteriorly</td>
<td>22</td>
<td>14</td>
<td>8</td>
</tr>
<tr>
<td>Sex distribution</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>31 (70.4)</td>
<td>14 (66.7)</td>
<td>17 (73.9)</td>
</tr>
<tr>
<td>Female</td>
<td>13 (29.5)</td>
<td>7 (33.3)</td>
<td>6 (26.1)</td>
</tr>
<tr>
<td>HP radiotherapy</td>
<td>5 (11.3)</td>
<td>2 (9.5)</td>
<td>3 (13)</td>
</tr>
<tr>
<td>Follow-up, years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>12.3</td>
<td>13.9</td>
<td>12</td>
</tr>
<tr>
<td>Quartiles</td>
<td>8.79 – 14.24</td>
<td>9.9 – 15.2</td>
<td>6.1 – 14</td>
</tr>
<tr>
<td>Reactivations</td>
<td>22 (50)</td>
<td>14 (66.7)</td>
<td>8 (34.8)**</td>
</tr>
</tbody>
</table>

Values are n (%), except where otherwise indicated. CA, chronological age; LCH, Langerhans cell histiocytosis; US, unisystem; UF, unifocal; MF, multifocal; MS, multisystem; LR, low risk; MRI, magnetic resonance imaging; HP, hypothalamic-pituitary; CDI, central diabetes insipidus. MSR was defined as those organs (liver, spleen, and/or haematologic system) that, when they are compromised, increase the risk of dying from the disease. MRI (n = 21). * p < 0.01; ** p < 0.04.
Time of follow-up was considered to be from CDI diagnosis until the last visit.

As shown in Figure 1 at the time of the study, 10 out of 64 patients were deceased (9 patients had disseminated LCH and 1 patient had an accident). Five other patients were lost to follow-up. Forty-nine patients were included in the follow-up analysis. For the analysis of follow-up data, patients were subdivided depending on the absence (group 1) or presence (group 2) of APD throughout the follow-up. Preliminary results on the time course of APD detection (online suppl. Fig. 1 and 2; for all online suppl. material, see www.karger.com/doi/10.1159/000452996) showed that 50% had developed APD at a median of 2.58 years of follow-up. Therefore, for the long-term follow-up analysis we included only those patients with 2.58 or more years from CDI diagnosis (no LCH diagnosis). Based on this criterion, long-term follow-up was analysed in 44 patients (Fig. 1). In addition, in each subgroup of patients the following variables: (1) the primary site of LCH at diagnosis: LR (including US and MS disease and hypothalamic-pituitary CNS involvement) and MS RO+ (MSR), (2) under or equal to 2 years of age at LCH diagnosis, and (3) the presence of reactivation were also analysed.

Statistical Analysis
Statistical analysis was performed using the package Statistix 7 (Analytical Software, Tallahassee, FL, USA) Copyright © 2000 Analytical Software. Categorical data were compared using the Fisher exact test and quantitative data with the Wilcoxon rank-sum test. A p of <0.05 was considered to be statistically significant.

The Kaplan-Meier analysis was used to estimate APD-free survival rates. The end point for survival analysis was the first-time appearance of APD. The period taken into account was the interval between LCH diagnosis and the event of APD or the last examination when no event occurred. Survival was compared between groups using the log-rank test. Proportional hazards regression was used to estimate the relative risk of developing APD associated with 1 unit increase for the independent variables.

Results
The clinical characteristics of the 64 patients with LCH associated with CDI are shown in online supplementary Table 1. As previously described, 44 patients were included in the long-term analysis (follow-up group). Median follow-up after CDI diagnosis was 12.3 years (interquartile range, 8.7–14.2). The clinical characteristics of the patients in the follow-up group are shown in Table 1. The primary sites of LCH at diagnosis were as follows: 15 (34%) patients had LR US disease and the remaining 29 (65.9%) patients had MS disease. Within the MS group, 19 (43%) patients had the LR clinical form and 10 (22.7%) patients had MSR. Skull bone risk lesions were observed in 91% of the patients.

An initial MRI was performed in 41 patients, revealing the following findings: absence of the neurohypophysis (n = 20), thickening of the pituitary stalk (n = 18), arachnoidocele/cyst (A) (n = 2), expansive lesions (tumour lesions) affecting the hypothalamic-pituitary region only (n = 4), and the brain or meninges (n = 4). Five patients had a normal MRI.

LCH, Langerhans cell histiocytosis; LR, low risk clinical form of LCH diagnosis unisystem and multisystem; CA, chronological age at LCH diagnosis; APD, antero-pituitary deficiency; CDI, central diabetes insipidus; RR, relative risk.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Coefficient</th>
<th>SD error</th>
<th>Z</th>
<th>p value</th>
<th>RR</th>
</tr>
</thead>
<tbody>
<tr>
<td>CA</td>
<td>0.13</td>
<td>0.05</td>
<td>2.34</td>
<td>&lt;0.01</td>
<td>1.14</td>
</tr>
<tr>
<td>Reactivation</td>
<td>-1.19</td>
<td>0.46</td>
<td>-2.59</td>
<td>&lt;0.01</td>
<td>0.3</td>
</tr>
<tr>
<td>LR</td>
<td>2.15</td>
<td>1.03</td>
<td>2.08</td>
<td>&lt;0.04</td>
<td>8.6</td>
</tr>
</tbody>
</table>

Statistically significant variables were:

- CA, chronological age at LCH diagnosis: RR 1.14, p < 0.01
- Fewer reactivation episodes: RR 0.3, p < 0.01
- LR clinical forms at LCH diagnosis: RR 8.6, p < 0.037

The Kaplan-Meier analysis, the comparative log-rank test showed a significant difference for the appearance of APD for age at LCH diagnosis (p < 0.02; Fig. 2a), LR clinical forms (p < 0.01; Fig. 2b), and absence of reactivation episodes (Fig. 2c) during the long-term follow-up (p < 0.01).

Multivariate Cox regression analysis confirmed that the appearance of APD was significantly associated with (1) higher CA at LCH diagnosis [relative risk (RR) 1.14, p < 0.01], (2) fewer reactivation episodes (RR 0.3, p < 0.01), and (3) LR clinical forms at LCH diagnosis (RR 8.6, p < 0.037) (Table 2). Similar results were obtained excluding patients with CNS tumours in the hypothalamic-pituitary region (data not shown).
Radiotherapy was not considered as a confounding variable, since there was a similar patient distribution within groups. In addition, very low radiotherapy doses were applied (10–15 Gy). GHD (45.4%) and TSHD (34%) were the most frequent APD associated with CDI, followed by gonadotropins deficiency (27%) and ACTHD (9%).

**Discussion**

This retrospective study of a large number of paediatric patients with LCH, selected based on the presence of CDI, showed that APD is more common when LCH diagnosis is made at an older age, the clinical form at diagnosis is US or MS LR, and the disease has less reactivation episodes.

LCH was originally described as 3 different entities: eosinophilic granuloma, Hand-Schüller-Christian disease, and Letterer-Siwe disease. In 1953, Lichtenstein [23] identified the common pathology (abnormal histiocytes) of these 3 entities of unknown aetiology and proposed the name of “histiocytosis X” (HX) for them. Later on, Nezelof and Bassett [24] showed that the lesional histiocytes in HX share a common phenotype with the Langerhans cells of the normal dermis, and, more specifically, they bear the same unique intracytoplasmic body called “Birbeck granula”. Since then, the term Langerhans cell histiocytosis gradually replaced HX. Although, a lot of progress has been made on LCH, predominantly in its clinical characterization and management, the pathogenesis is still controversial.

In agreement with reports in the literature on risk factors for developing CDI [1–3, 11, 13, 17, 25–27], in this study, a predominance of MS disease, skull bone risk lesions, and reactivation episodes was observed. It is well recognised that APD appears during the course of the dis-
ease in patients affected by CDI [10, 15, 17]; however, and similar to the findings of another study [17], only 23 patients (52.2%) developed APD during the long-term follow-up.

There is scarce information on the risk factors for developing APD, especially in LCH patients with CDI [17, 25, 28, 29]. In a previous report [17], the authors described 2 early findings – premature loss of growth velocity and decreased anterior pituitary height on the MRI – as predictive variables for APD. Although we were not able to analyse these factors, using multivariate Cox regression analysis, we found 3 significant factors predictive of APD development: (1) older age at the diagnosis of LCH, (2) US or MS LR at the diagnosis of LCH, and (3) less reactivation episodes during follow-up. Older age at the diagnosis of LCH could be explained by a delay in the diagnosis of this heterogeneous disease and, consequently, a deferral in treatment initiation. The latter situation might condition a different outcome of the same disease. On the other hand, the more frequent involvement of LR organs in the APD group may suggest a different pathogenic origin of DC. In keeping with these data, Berres et al. [30] postulated that the developmental stage of pathological DC precursors defines the extent of the disease and consequently the different clinical presentations. Interestingly, Donadieu et al. [31] stated that MSR LCH associated with haematologic and liver involvement was not associated with an increased risk of pituitary involvement either with CDI or APD.

Disease reactivations have been related to an increased risk of pituitary involvement [11, 13, 31, 32]. Nevertheless, reactivations were significantly less in the APD group. The reason of this discrepancy might be related to the fact that in the analysis of CDI groups, the discrimination between the presence or absence of APD is frequently not included in data analysis.

A different embryological origin of the antero- and neurohypophysis may determine a different immune effect. The mechanism of APD is still poorly understood. However, different possibilities have been proposed, such as: (1) infiltration of the hypothalamic region causing both deficiencies of antidiuretic hormone and hypothalamic releasing factors and/or infiltration of the anterohypophysis, (b) microinjury leading to vascular impairment and scarring [33], and (c) immune modulation of cytokines from adjacent osseous lesions or an autoimmune effect [13, 34].

In agreement with the literature [9, 15, 17, 25, 28, 35], GHD was the most and corticotrophin-releasing hor-
References


Paediatric LCH: Predictor Variables of Anterior Pituitary Deficiencies